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Abstract: One of the main factors able to explain the pathophysiological mechanism of 
inflammatory conditions that occur in periodontal disease is oxidative stress. Given the 
emerging understanding of this relationship, host-modulatory therapies using antioxidants 
could be interesting to prevent or slow the breakdown of soft and hard periodontal tissues. 
In this context, non-nutrient phenolic compounds of various foods and plants have received 
considerable attention in the last decade. Here, studies focusing on the relationship 
between different compounds of this type with periodontal disease have been collected. 
Among them, thymoquinone, coenzyme Q (CoQ), mangiferin, resveratrol, verbascoside 
and some flavonoids have shown to prevent or ameliorate periodontal tissues damage in 
animal models. However evidence regarding this effect in humans is poor and only limited 
to topical treatments with CoQ and catechins. Along with animal experiments, in vitro 
studies indicate that possible mechanisms by which these compounds might exert their 
protective effects include antioxidative properties, oxygen and nitrogen scavenging 
abilities, and also inhibitory effects on cell signaling cascades related to inflammatory 
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processes which have an effect on RNS or ROS production as well as on antioxidant 
defense systems. 
Keywords: anti-inflammatories; phytochemical; periodontitis; polyphenols 
 
1. Introduction 
Periodontal diseases are chronic inflammatory conditions characterized by loss of connective tissue, 
alveolar bone resorption and formation of periodontal pockets as a result of the complex interaction 
between pathogenic bacteria and the host’s immune response [1]. At present, periodontitis, its 
destructive phase, is considered to be initiated and perpetuated by a small group of predominantly 
Gram-negative, anaerobic, or micro-aerophilic bacteria that colonize the subgingival area. Bacteria 
cause the observed tissue destruction directly by toxic products and indirectly by activating host 
defense systems, i.e., inflammation [2]. Inflammation is a localized protective response of the 
organism to a noxious stimulus, whether mechanical, chemical, or infectious, which serves to destroy, 
dilute, or wall off both the injurious agent and the injured tissue [3]. Whether acute or chronic, 
inflammation is dependent upon regulated humoral and cellular responses, and the molecules 
considered to mediate inflammation at one time or another are legion [4]. As a consequence of the 
multitude of processes that it implies, inflammation entails the production of an amount of energy 
sufficient to support all necessary biochemical reactions and the output of all mediators, such as 
proteins. Most of the energy is produced in the mitochondria via the electron-transport chain that 
implies an oxidation process with oxygen as the main combustive agent [3]. 
One of the main factors able to explain the pathophysiological mechanism of inflammatory conditions 
that occur in periodontal diseases is oxidative stress [5], and, recently, its complex role in relation to 
periodontal breakdown has been comprehensively reviewed [6,7]. Reactive oxygen species (ROS) are 
essential to many physiological processes but when an antioxidant system is unable to efficiently 
counteract their action, tissue and cell damage can result, enhancing periodontal destruction [6]. This 
aspect is in accordance with a recent study reporting new evidence that chronic periodontitis, as  
a common potential source of low-grade inflammation, could be associated with a systemic oxidative 
stress state and reduced overall antioxidant capacity [8]. In this sense, Porphyromonas gingivalis 
lipopolysaccharide (LPS) was found to be responsible for high mitochondrial ROS and for 
mitochondrial dysfunction because it affected the amount of respiratory chain complex I and III [9,10]. 
Furthermore, high levels of mitochondrial-derived ROS, accompanied by mitochondrial dysfunction, 
in peripheral blood mononuclear cells (PBMCs) from patients with periodontitis [11] have been 
reported, and several studies have demonstrated an increase in products from oxidative damage in 
plasma and serum of subjects with periodontitis compared with healthy individuals [12–14]. Likewise, 
there is increasing evidence for a decreased antioxidant capacity in periodontal tissues and fluids of 
subjects with periodontitis [7,15,16]. Additionally, damage mediated by ROS in periodontal diseases 
also results from the physiological activity of phagocytosing leukocytes, i.e., polymorphonuclear 
neutrophils (PMN) during the “respiratory burst” [6,17]. An event characteristic of mammalian 
inflammation, tissue infiltration by PMNs and monocytes and subsequent phagocytosis, features a 
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burst of non-mitochondrial O2 consumption, which may be 10 or 20 times that of resting consumption. 
Oxygen uptake in neutrophils and macrophages is due to the action of a plasma-membrane-bound 
flavoprotein cytochrome b245 NADPH oxidase system that increases NADPH production via the 
hexose monophosphate shunt and generates superoxide anion radicals, hydrogen peroxide, hydroxyl 
radicals and hypochlorous acid, all capable of damaging either cell membranes or associated 
biomolecules [6]. Moreover, among the inflammatory mediators produced there is nitric oxide  
(NO) [18], which also is a highly reactive free radical. Due to this feature it can react with certain 
biological molecules or other reactive species leading to different cytotoxic nitrogenated  
compounds [19]. The interactions of NO with other oxidants are especially important since they may 
give rise to a free radical cascade and formation of reactive nitrogen species (RNS) such as 
peroxynitrite [20]. Consequently, a variety of molecular oxidative species appears in the inflamed 
tissues, including RNS and ROS. Actually, several forms of periodontal disease have been often 
associated with functionally activated PMN exhibiting increased ROS production [6]. Thus, the  
up-regulation of pro-inflammatory transcription factor in inflamed periodontal tissues contributes to 
antioxidant depletion and reactive molecular species generation [17,21]. Moreover, some oxidation 
products can increase neutrophil adhesion, chemotaxis and priming in hyper-reactive neutrophils, and 
might augment the damaging effects of the resultant oxidative stress [22–24]. 
Given the emerging understanding of the role of oxidative stress in periodontal disease,  
host-modulatory therapies using antioxidants could be interesting to prevent or slow the breakdown  
of soft and hard periodontal tissues [25]. Antioxidants are substances that, when present at low 
concentrations compared with oxidizable substrates, can significantly delay or prevent oxidation of 
those susceptible substrates [6]. Thus they constitute an efficient defense system against the oxidative 
damage induced by reactive molecular species [2,6]. Their specific role is to remove or inactivate 
reactive molecular species, or to repair damage caused by them. However, when the former fails to 
efficiently counteract reactive molecule action, tissue damage can result [6,17]. Based on the way they 
act [3], antioxidants are functionally classified as preventive antioxidants, radical scavengers and 
repair and de novo enzymes [3,6]. Natural products can play an important role in the prevention  
and treatment of periodontal diseases [26,27] because many of them have anti-oxidative and  
anti-inflammatory properties [25]. In this context, non-nutrient phenolic compounds of various foods 
and plants have received considerable attention in the last decade [28]. In order to explore this issue,  
a search without restrictions was conducted in the PubMed database (Nationtal Insitute of Health, 
Washington, DC, USA) combining the terms “antioxidant”, “periodontal disease” and “food”, and 
accessible items that evaluated only naturally occurring compounds both in vivo and in vitro were 
considered. After read them, it was found that possible mechanisms by which these compounds might 
exert their protective effects included antioxidant properties, oxygen and nitrogen scavenging abilities, 
but also inhibitory effects on cell signaling cascades related to inflammatory processes which have 
effect on RNS or ROS production as well as on antioxidant defense systems. As a result, it is not easy 
to differentiate between antioxidant and immunomodulatory effects. For this reason, in the present 
review, we collect different phenolic compounds whose possible role based on any of these 
mechanisms have been evaluated in relation to periodontal disease (Table 1). 
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2. Thymoquinone 
Thymoquinone (2-isopropyl-5-methyl-1,4-benzoquinone), a benzoquinone derivative, is the main 
constituent of the volatile oil from Nigella sativa seeds. This compound has a range of pharmacologic 
properties, among these its antioxidant effect is considered to be one of its most significant. It has been 
reported that thymoquinone induces an antioxidant response through the scavenging capability of 
various free radicals, with its scavenging power being as effective against superoxide anions as 
superoxide dismutase [29]. Thymoquinone has also been argued to have anti-inflammatory potential 
through membrane lipid peroxidation, via eicosanoids [30]. In rats, ligature placement on mandibular 
first molars was associated with higher alveolar bone loss, an increase of inflammatory cell infiltrate 
and osteoclast number and a decrease of osteoblastic activity, which did not occur when animals 
simultaneously received thymoquinone by gastric feeding [25]. Considering both, anti-inflammatory and 
antioxidant properties, as well as the effects on alveolar bone loss and expression of proinflammatory 
cytokines, thymoquinone likely presents a new aspect in the prevention and treatment of periodontal 
disease preventing the initiation and progression of periodontitis. 
3. Coenzyme Q 
Coenzyme Q (CoQ) is a naturally occurring coenzyme formed from the conjugation of a 
benzoquinone ring with a hydrophobic isoprenoid chain of varying chain length, depending on  
the species [31]. In particular, the chemical nomenclature of CoQ10 is 2,3-dimethoxy-5-methyl-6-
decaprenyl-1,4-benzoquinone that is in the trans configuration (natural) [32]. Due to its ubiquitous 
presence in nature and its quinone structure (similar to that of vitamin K), CoQ is also known as 
ubiquinone [33]. It is found in every plant and animal cell and is located in the inner membrane system 
of the mitochondria, other membranes and in plasma lipoproteins [34]. It exists in two molecular 
forms, ubiquinone, the oxidized form, and ubiquinol, the reduced form, which are the basis for its 
antioxidant properties [35]. Ubiquinone molecules are classified based on the length (n) of their 
isoprenoid side chain (CoQn) [31]. CoQ9 is the predominant form in relatively short-lived species such 
as rats and mice whereas in humans and other long-living mammals the major homolog is CoQ10 [36]. 
Ubiquinone is also referred to as “coenzyme” because of its unique ability to participate in chemical 
reactions but remain at steady-state levels in the cell [37]. The well-recognized function of CoQ is 
mitochondrial energy coupling. It is an essential part of the cellular machinery used to produce ATP in 
the inner membrane of mitochondria where this process mainly takes place [34]. The other important 
function is that it acts as a primary scavenger of free radicals as it is well located in the membranes in 
close proximity to the unsaturated lipid chains. Less well-established functions also include 
oxidation/reduction control of signal origin and transmission in cells, which induce gene expression, 
control of membrane channels, membrane stabilization and lipid solubility [34]. As it is an antioxidant, 
CoQ has received much research attention in the medical literature in the last several years [38]. 
Studies have demonstrated that CoQ has anti-oxidative effects and anti-aging properties at the skin 
level [39]. Among its possible applications, CoQ is recommended as a supplement to traditional 
therapy for cardiovascular diseases [40].  
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Human cells are able to synthesize CoQ10 from the amino acid tyrosine, in an eight-step aromatic 
pathway, requiring adequate levels of vitamins such as folic acid, niacin, riboflavin and pyridoxine [41]. 
Since CoQ10 is synthesized de novo in all tissues, it is presumed that under normal circumstances  
they are not dependent on an exogenous supply of CoQ10. However, situations may arise in which  
the body’s synthetic capacity is insufficient to meet CoQ10 requirements. Susceptibility to CoQ10 
deficiency appears to be greatest in cells that are metabolically active (such as those in the heart, 
immune system, gingiva and gastric mucosa), since these cells presumably have the highest 
requirements for CoQ10 [33]. A deficiency of CoQ10 has been found in the gingival tissue from patients 
with periodontal disease [42,43], as well as in their peripheral blood mononuclear cells (PBMCs) [11]. 
Nevertheless, CoQ10 deficiency in the gingiva may exist independently of and/or because of 
periodontal disease [42,44]. Moreover, it has also been found that CoQ10 remained unchanged in the 
periodontally affected tissues during gingivitis despite other antioxidant, such as vitamin E, being 
dramatically decreased [45]. If a deficiency of CoQ10 existed in gingival tissue for nutritional causes 
and independent of periodontal disease, then the advent of periodontal disease could enhance the 
gingival deficiency of CoQ10 [42]. In such patients, oral dental treatment and oral hygiene procedures 
can remove just the local factors (plaque and calculus) but cannot correct the systemic deficiency of 
CoQ10 [42]. Thus, it has been suggested that mechanical periodontal therapy along with the adjunctive 
use of CoQ should be included for an improved treatment of this type of periodontal disease [42,44]. 
Many clinical trials with oral administration of CoQ to patients with periodontal disease have been 
conducted. The results have shown that oral administration of CoQ10 increases the concentration of 
CoQ10 in the diseased gum and effectively suppresses periodontal inflammation [46,47]. Furthermore, 
they indicated that CoQ10 might reduce gingival inflammation without affecting total antioxidant levels 
in the gingivocrevicular fluid [48]. Oral administration of CoQ combined with vitamin E has also 
shown a beneficial effect on the periodontal tissue, since periodontal pockets shallowed by 30% 
accompanied by a decrease of several clinical outcomes (including plaque index, interdental hygiene 
index, gingival index and sulcus bleeding index) [49]. In addition to oral administration, other uses of 
CoQ also offer promising results. In rats, ubiquinol (reduced form of CoQ) applied topically on the 
gingival surface suppresses age-related inflammatory reactions, the mechanism for this is suggested to 
be the lower gene expression of caspase-1, interleukin(IL)-1β and Nod-like receptor protein 3 
inflammasomes in the periodontal tissue. It also leads to a differentiation of osteoclasts associated with 
aging, probably by inhibiting oxidative stress as indicated by a decreased oxidative DNA damage [50]. 
Topical application is a convenient method in the dental clinical setting, and clinical trials evaluating 
benefits of CoQ topical (i.e., extrasulcular) application (in gel-form) also exist in humans [38,51,52]. 
Moreover, intra-pocket application was tested as well in the same trials [38,51]. These studies showed 
that both types of application of a gel containing CoQ10 for 6 weeks improved major clinical 
parameters. Further, CoQ10 use has also been tested after a scaling and root planning treatment [38,51], 
and its application combined with mechanical treatment offered better results, but only when the gel 
was applied to the periodontal pockets [38]. 
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4. Gallic Acid 
Gallic acid (3,4,5-trihydroxybenzoic acid) is an endogenous plant phenolic acid found abundantly in 
tea, grapes, berries and other fruits as well as in wine [53–55]. It is also found in some hard wood plant 
species such as oak (Quercus robur) or chestnut (Castanea sativa L.) [56,57]. Among others, gallic 
acid is known to have strong antioxidant [58] and anti-inflammatory [59] properties. Treatment with 
this compound in non-toxic concentrations revealed a strong inhibitory effect on NO production without 
affecting iNOS expression in murine macrophage-like cells (RAW 264.7 cells) stimulated with LPS  
of Aggregatibacter actinomycetemcomitans (previously Actinobacillus actinomycetemcomitans) or 
Fusobacterium nucleatum, two major bacteria implicated in periodontitis [60]. However, it slightly 
increased ROS production in them. In spite of these effects, it did not show stronger activity than other 
phenolic compounds also tested in the same assay, more research on gallic acid therapeutic use could 
lead to interesting results due to its simplicity and availability. 
5. Hydroxytyrosol 
Hydroxytyrosol (3,4-dihydroxyphenylethanol) is a phenylethanoid [61] that comes from the 
hydrolysis of oleuropein, which originates during the maturation of olives, storage of the oil and 
preparation of table olives. These processes give rise to hydroxytyrosol along with oleuropein 
aglycone and elenolic acid, that are responsible, in part, for the complex and varied flavor of the oil 
and olive [62]. As a consequence of their polar character, phenolic compounds such as hydroxytyrosol 
are found in great quantities in the remains from oil processing, such as pomace olive oil, olive-mill 
waste water, or the rinse waters. For this reason, byproducts from olive oil production constitute a 
major source of hydroxytyrosol. Nevertheless, hydroxytyrosol also has an amphipathic behavior, and 
the molecule is therefore found in olive oil [62,63]. Additionally, it is also located in the olive leaf, 
where it is accompanied by other phenolic compounds such as oleuropein [64]. To date, 
hydroxytyrosol has been demonstrated in numerous studies to have antiatherogenic, anti-inflammatory 
and antitumor effects, which have been widely reviewed [65]. Regarding the periodontum, a study in 
rabbits reported a certain anti-inflammatory effect of supplementation with hydroxytyrosol. 
Specifically, it was reported that it reduced endothelial activation in rabbits that had developed 
atherosclerosis induced by a diet rich in saturated fats, but it did not improve endothelial activation and 
lower cellularity in gingival mucosa, which are also associated with this pathology [66]. However, 
there is no data regarding its effect on alveolar bone or periodontal oxidative stress levels. In that 
sense, a more recent study has shown that a virgin olive oil-based diet decreased alveolar bone 
breakdown associated with aging in rats, which is associated with lower gingival lipid peroxidation 
and increased systemic levels of major proinflammatory cytokines [67]. At present, it is well 
established that the health benefits of olive oil are not concentrated solely in its fatty-acid content [65], 
since it has been noted that refined olive oil (free of phenols) lacks the antioxidant effects present in 
virgin olive oil [68,69], whereas the phenolic fraction of olive oil considerably improves the lipid 
peroxidation of LDL lipoproteins, which is related to an increase in antioxidant capacity [70]. 
The oil also includes several bioactive compounds with high antioxidant capacity, such as  
hydroxytyrosol [71,72]. 
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6. Mangiferin 
Mangiferin is a glycosylated xanthone (C2-b-D-glucopyranosyl-1,3,6,7-tetrahydroxyxanthone), 
generally called C-glucosyl xanthone, widely distributed in higher plants [73,74], and it is the 
predominant constituent (10%) of mango (Mangifera indica L.) extract which belongs to the family 
Anacardiaceae [75,76]. This plant, which grows in tropical and subtropical regions, is widely used in 
folk medicine for various therapeutic indications [75]. Based on the various studies done on 
mangiferin, it possesses a wide range of pharmacological actions including anti-inflammatory [77], 
antioxidant [76], antidiabetic [78], immunomodulatory and antitumor effects [79]. Based on this 
bioactivity exhibited by mangiferin, growing attention has been given to its medical significance for 
human health [80]. In particular, it has been demonstrated that it has bone anti-resorption activity in 
lumbar vertebrae in an experimental model using a dose of 100 mg/(kg·day) [81]. Oral administration 
of mangiferin significantly reduced alveolar bone loss in a rat model after periodontitis induction by 
ligatures placement. This could be due to its inmunomodulatoy effects since bone loss prevention was 
accompanied by a reduction of cellularity, a decrease in COX-2 expression and an inhibition of rolling 
and adhesion of leukocytes. Curiously, mangiferin-treated rats presented an earlier peak of cell 
proliferation and augmented angiogenesis in the injured region [82] than controled animals. 
7. Resveratrol 
Resveratrol (trans-3,4ʹ,-5-trihydroxystilbene) is a widely available stilbenoid found in several 
plants, including berries, peanuts [83–85] and, in particularly high concentrations, grape skins and red 
wine [86]. Numerous studies on resveratrol have demonstrated a variety of biologic properties with 
health benefits [87–90]. Among these, it has also been shown that resveratrol may positively interfere 
with osteoblastogenesis, contributing to new bone formation [91]. These properties could be very 
useful for periodontitis treatment. Resveratrol administration in drinking water has shown to lead to 
relieved alveolar bone resorption associated with ligature placement [92]. Further, continuous systemic 
administration of resveratrol also decreased periodontal breakdown induced by similar methods [28], 
confirming the positive effects of resveratrol on these types of models. 
Traditionally, many of the health benefits of resveratrol have been attributed to its antioxidant 
properties, as it is a known scavenger of superoxides, hydroxyl radicals and peroxynitrites [84]. In 
addition, resveratrol induces antioxidant enzyme activities [87,93] and activates the nuclear factor  
E2-related factor (Nrf2) antioxidant defense pathway. When Nrf2 is activated, it translocates to the 
nucleus, where it mediate the transcription of target genes which enhances cellular resistance to 
oxidative stress and confers protection against inflammation such as heme oxygenase 1 (HO-1) and 
NAD(P)H:quinine oxidoreductase 1 (NQO-1) [94]. In that sense, resveratrol also enhances 
mitochondrial biogenesis through the activation of AMP-activated protein kinase (AMPK) via sirtuin 1 
(Sirt1), an NAD-dependent nuclear class III histone deacetylase [95,96]. The combination of these 
mechanisms would reduce ROS levels and mitochondrial dysfunction explaining that in the 
periodontitis rat models cited, alveolar bone loss prevention by resveratrol was associated  
with the improvement of the systemic levels of different oxidative stress markers including  
8-hydroxydeoxyguanosine (8OHdG), dityrosine and nitrotyrosine [92]. In addition, down-regulation of 
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the inducible NO synthase (iNOS) expression by resveratrol was also noted [97] reducing NO 
production, which would collaborate in oxidative stress reduction. This last point could result from 
resveratrol’s immunomodulatory effect since the systemic levels of some proinflammatory cytokines also 
decreased [28,92]. Therefore, according to animal experiments results, resveratrol might prevent the 
progression of periodontal disease, presenting a promising, innovative host-modulatory therapeutic 
approach in the treatment of periodontitis [28]. 
8. Verbascoside 
Verbascoside or acetoside is a phenylpropanoid glycoside isolated from some Lamiaceae  
plants, which is structurally characterized by a caffeic acid (phenylpropanoid moiety) and  
4,5-hydroxyphenylethanol (phenylethanoid moiety) bound to a b-(D)-glucopyranoside [98,99]. 
Recently, it has been demonstrated that it promotes skin repair and ameliorates skin inflammation due 
to its ROS-scavenging, antioxidant, iron-chelating and glutatione-S-transferase (GST)-inducing  
properties [100]. A rat model of periodontitis showed interesting effects in relation to periodontal 
tissues for this compound. In this study, oral administration of verbascoside (in this case, 
biotechnologically produced by Syringa vulgaris plant cell cultures) exerted an anti-inflammatory role 
and ameliorated the tissue damage associated with ligatures placement. The reduction of damage was 
related to a reduction in oxidative stress levels, which could be mediated by the observed reduction in 
myeloperoxidase (MPO), iNOS and NO levels. It seems that both effects may be due to verbascoside 
preventing the ligature-induced IkB-α (nuclear factor of kappa light polypeptide gene enhancer in  
B-cells inhibitor, α) degradation and consequently also nuclear factor-κB (NF-κB) translocation to the 
nucleus in gingivomucosal tissue (To have a representation of main cell signaling routes described along 
this text, see Figure 1) [98]. Verbascoside is also found in olive fruits [101], but because of it is a  
water-soluble compound, its presence in virgin olive oil probably is much reduced compared with 
other phenolic compound as hydroxytyrosol. 
9. Flavonoids 
Flavonoids constitute a group of naturally occurring polyphenolic compounds found in a large 
number of plants and vegetables [102] that have structures consisting of three rings (two of them 
aromatic) which are labeled A, B and C [103]. More than 4000 varieties of flavonoids have been 
identified, many of which are responsible for the attractive colors of flowers, fruits and leaves [102]. 
These can be divided into five subcategories: flavonols, flavones, flavanols, flavanones and 
anthocyanidines [26,104,105]. Different flavonoid classes differ in the levels of oxidation and pattern 
of substitution of the C ring, whereas individual compounds within a class differ in the pattern of 
substitution of the A and B rings [103]. They possess a wide spectrum of biologic activities,  
including antioxidant, anticarcinogenic, antiangiogenic, anti-inflammatory, antiallergic and antiviral  
properties [103,106–108]. Because of these, different flavonoids have been studied in relation to 
periodontal diseases as therapeutical or preventive agents. The major compounds researched in this 
topic and belonging to the different flavonoid subcategories are presented below. 
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9.1. Flavonols 
9.1.1. Quercetin 
Quercetin (3,5,7,3ʹ,4ʹ-pentahydroxyflavone) is an abundant flavonol-type flavonoid [109,110]. 
Foods rich in quercetin include apples, black and green tea, onions, red wine, red grapes, citrus fruit, 
broccoli and other leafy green vegetables, cherries, and a number of berries including raspberry, 
lingonberry and cranberry [111]. The effects of quercetin on a variety of inflammatory processes and 
immune functions have been reviewed [112–114]. Moreover, the United States Food and Drug 
Administration (FDA) has approved it as an ingredient in over-the-counter health supplements. The 
generally recommended adult dose of quercetin for general health benefits is 200–500 mg daily, and 
up to 1000–1500 mg a day can be consumed [112] and to date, there has been no evidence in the 
literature of any adverse effects from consuming quercetin [110]. Interestingly, it has been observed 
that quercetin has potent local osteogenic effects in rabbits [115]. At the periodontal level, it has been 
demonstrated that the oral administration of Quecetin inhibits bone loss, as well as inflammation, in 
rats with periodontitis induced by ligatures [116]. Protective effect of quercetins on alveolar  
bone loss was also reported in a mouse periodontitis model induced by A. actinomycetemcomitans 
infection [109]. This effect has also been related to lower active osteoclasts induced by LPS [116]. 
This effect seemed due to modulation of cytokine production at least in part, since it was accompanied 
by a decrease of interleukin IL-1β, tumor necrosis factor-α (TNF-α), IL-17, receptor activator of  
NF-κB ligand (RANKL), and inducible cell adhesion molecule (ICAM-1) in the gingival tissue, but it 
has no effect on bacterial counts [109]. Quercetin also has shown a clear antioxidant effect in the oral 
cavity against NO, which results of nitrite reduction by certain oral bacteria. This occurs at expense of 
quercetin oxidation, so its effect disappears when all quercetin is oxidized. For this reason, it has been 
suggested that quercetin can protect human oral cavity from damage induced by RNS and that the 
protective function of quercetin may be significant when antioxidant capacity of saliva is decreased  
by periodontal diseases [117]. Consequently, quercetin is an antioxidant molecule with a potential  
anti-inflammatory action [94,118,119] also on periodontal tissue. For this reason it has been suggested 
that it may have an ameliorative effect on periodontal destruction. [116]. 
9.1.2. Kaempferol 
Another flavonol, kaempferol (3,5,7-trihydroxy-2-[4-hydroxyphenyl]-4H-1-benzopyran-4-one),  
which is widely found in fruits, vegetables and tea [120] has also shown strong antioxidant and  
anti-inflammatory properties [107,108,120] among a variety of pharmacologic activities [120]. 
Specifically, there is increasing evidence that kaempferol is potentially immunomodulatory in  
LPS-stimulated cells. Kaempferol was able to reduce cytokines and chemokines produced by  
LPS-stimulated dendritic cells [121] and inflammatory mediators induced by LPS in microglial  
cells as well [122]. This suggests that kaempferol has a potential in the treatment of chronic 
inflammatory and autoimmune diseases [121,122]. Likewise, it inhibited LPS-induced production of 
monocyte chemoattractant protein-1 (MCP-1), which is involved in the pathogenesis of cardiovascular 
and neurodegenerative disorders, in macrophages [123]. However, the potential of kaempferol as a 
therapeutic agent for treating periodontal disease is little studied. In that sense, it has been reported  
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that kaempferol strongly inhibits LPS-induced production of NO at the translational level by 
Prevotella intermedia, another periodontopathogen [124]. In an in vitro study with P. intermedia  
LPS-stimulated RAW246.7 cells, this compound significantly inhibited NO production via HO-1-mediated 
intracellular ROS reduction since it had not affect iNOS mRNA expression, but upregulated HO-1. In 
fact, inhibition of HO-1 activity by tin protoporphyrin IX (SnPP) abolished the suppressive effect of 
kaempferol on the production of NO and intracellular ROS [124]. 
9.1.3. Isorhamnetin 
Isorhamnetin (3ʹ-methoxy-3,4ʹ,5,7-tetrahydroxyflavone) is a flavonoid found in apples,  
blackberries, pears and sea buckthorn [125] and it is also an immediate metabolite of quercetin, at least 
in mammals [126]. Isorhamnetin has been reported to have many biological properties, including 
antioxidant and anti-inflammatory activities [127,128]. As consequence it has been tested as potential 
therapeutic agent in periodontal disease. In RAW264.7 cells stimulated with P. intermedia LPS, 
isorhamnetin significantly down-regulated P. intermedia LPS-induced production of IL-6 as well as its 
mRNA expression, which suggests that this compound may contribute to blockade of some  
host-destructive processes, at least of those mediated by IL-6. As with the previous flavonols, an  
up-regulation of HO-1 expression was also noted, which occurred at both transcriptional and 
translational levels. This seems one of the pathways of the inflammatory effect, since inhibition of 
HO-1 activity by tin protoporphyrin IX blocked the inhibitory effect of isorhamnetin on IL-6 
production. However, isorhamnetin failed to prevent LPS-induced activation of either c-Jun N-terminal 
kinase (JNK) or p38 pathways. On the other hand, it suppressed NF-kB signaling through inhibition of 
nuclear translocation and DNA binding activity of NF-kB p50 subunit by attenuation of signal 
transducer and activator of transcription 1 (STAT1) signaling [129]. 
9.2. Flavones 
9.2.1. Luteolin 
Luteolin (3,4ʹ,5,7-tetrahydroxyflavone) is a flavone found at high concentrations in celery, green 
pepper, parsley, perilla leaf and seeds and chamomile. As for other flavonoids, a range of biologic and 
pharmacologic activities of luteolin have been reported [130]. Actually, it has been described as the 
most potent and efficient inhibitor of TNF-α, IL-6, and NO expression in LPS-stimulated  
macrophages [131]. For this reason, its efficacy as potential anti-inflammatory compound to treat 
periodontal disease has been also studied in vitro. In human gingival fibroblasts [132] and in murine 
RAW264.7 cells [26], luteolin pretreatment suppressed LPS-induced NO synthesis, which had been 
reported to occur in a dose-dependent fashion [26]. Moreover, its effects also include an inhibition of 
IL-6 release in the macrophage-like cells [132]. These effects were related to a reduction of various  
mitogen-activated protein kinase (MAPK) family members (including extracellular signal-regulated 
kinase [ERK], p38, and Akt) activation by phosphorylation [132], which finally prevents NF-κB 
translocation to the nucleus [26,132]. Furthermore, a reduction of NF-κB p50 subunit DNA binding 
activity and a suppression of the signal transducer and activator of transcription (STAT) pathway 
signaling [26] have also been observed. Consequently, iNOS expression would be inhibited explaining 
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the effects of luteolin on NO levels. In addition, luteolin treatment blocked LPS-induced cellular 
proliferation inhibition without affecting genetic material integrity in fibroblasts [132], but it remains 
unknown if this was due to its actions on a different pathway. 
 
Figure 1. Main phenolic compound effects on cell signaling pathways and enzyme 
implicated on oxidative/nitrosative stress and inflammation. Acronyms and 
Abbreviations. COX2: Cyclooxygenase, ERK: Extracellular signal-regulated kinases, 
HO-1: Heme oxygenase 1, IKKα: IB kinaseα, IKKβ: IκB kinase β, IL-1: Interleukin 1, 
IL-1R: Interleukin 1 receptor, IL-6: Interleukin 6, IL-6R: Interleukin 6 receptor, IκBα: 
Inhibitor of κ light polypeptide gene enhancer in B-cells α, JAK: Janus kinase,  
JNK: c-jun terminal kinase, L-Arg: L-Arginine, MAPK: Mitogen-activated protein 
kinases, NfκB: Nuclear factor kappa-light-chain-enhancer of activated B cells, LPS: 
Lypopolysaccharide, PGs: Prostaglandins PI3K: Phosphoinositide 3-kinase, PKB: Protein 
kinase B, RANK: Receptor activator of nuclear factor κB, RANKL: Receptor activator of 
nuclear factor κB ligand, RNS: Reactive nitrogen species, ROS: Reactive oxygen species, 
STAT: Signal transducer and activator of transcription, TFDG: Theaflavin digallate, 
TLR: Toll-like receptor 2/4, TNF: Tumor necrosis factor α, TNFR: Tumor necrosis factor 
α receptor. 
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9.2.2. Baicalin 
Baicalin (7-glucuronic acid, 5,6-dihydroxy-flavone) is a flavonoid compound purified from the 
medicinal plant, Scutellaria baicalensis georgi [133,134]. Baicalin has also been found to exert several 
biological activities, which are mainly related to its antioxidant properties and to its ability to inhibit 
enzymes and regulate the immune response [133,135–138]. In addition, it has been used as an  
anti-inflammatory agent in the treatment of a variety of inflammatory diseases [135,139], which could 
extend to peridontal diseases as suggested in an experiment in animals. In this, rats with periodontitis 
induced by ligatures, presented less alveolar bone loss and a higher area fraction of collagen fibers 
when they were fed baicalin by oral gavage, which correlated with down-regulation of protein levels 
for cyclooxygenase-2 (COX-2) and iNOS [135]. Similarly, baicalin has been found to inhibit COX-2 
activity in a castor-oil-induced diarrhea model, as well as to inhibit iNOS expression in LPS-treated 
RAW 264.7 cells [140,141].  
9.2.3. Apigenin 
Apigenin, has been found to possess various anti-inflammatory activities useful for different 
pathologies [26,142,143]. Specifically, apigenin inhibits NO and iNOS synthesis a well as production 
of several proinflammatory mediators (such as prostaglandin E2, COX-2, and TNF-α), through the 
suppression of the NF-κB pathway or the STAT pathways [144–148]. In nicotine- and LPS-stimulated 
human periodontal ligament cells, incubation with apigenin significantly inhibited the nicotine- and 
LPS-induced production of NO and the up-regulation of iNOS. Moreover, as with other compounds, it 
was also accompanied by an inhibition of the COX-2 and several proinflammatory factors (PGE2,  
IL-1β, TNF-α, IL-6, and IL-12) up-regulation. These effects have been attributed to a decrease of  
LPS- and nicotine-induced HO-1 protein expression and activity, since the selective HO-1 inducer 
Hemin reversed the apinengin effect on NO, PGE2 and cytokine production were reversed. On the 
other hand, inhibitors of the phosphoinositide 3-kinase, p38, JNK, and protein kinase C also blocked 
the anti-inflammatory effects of apigenin in these cells [144]. In spite of the understanding of this 
control pathway, data regarding its effect on periodontal tissue inflammation or breakdown are  
not available. 
9.2.4. Nobiletin and Tangeretin 
Nobiletin (5,6,7,8,3′,4′-hexamethoxy flavone) and tangeretin (5,6,7,8,4′-pentamethoxy flavone) are 
abundantly present in orange peel, and they exhibit several biological activities [149,150]. In 
particular, nobiletin has shown to be useful for the treatment of pathologies related to inflammatory 
disorders [149,151]. Nobiletin markedly suppresses bone resorption and restores the bone loss in 
ovariectomized mice, a model of postmenopausal osteoporosis [152]. In a short communication, it has 
been reported that both compounds suppress LPS-induced osteoclast formation and bone resorption 
and suppress the RANKL-induced osteoclastogenesis in RAW264.7 cells. Moreover, nobiletin clearly 
restored the alveolar bone mass in a mouse periodontitis model for periodontitis by inhibiting  
LPS-induced bone resorption. These results indicate that the use of both flavonoids constitutes a new 
therapeutic approach for periodontal bone loss [150], but more details about their effect are needed. 
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9.3. Flavans 
9.3.1. Catechins 
Catechins are naturally occurring polyphenolic compounds that are very numerous in green tea to 
which beneficial effects on human health have been largely attributed [153–155]. Research to date 
suggests that catechins have various biological effects including cardiovascular disease prevention [156] 
and increase of glucose tolerance [157]. Among others, these compounds have shown antibacterial [158], 
anti-inflammatory, antioxidant [159] and free radical scavenging properties [160,161], which are 
interesting for periodontal diseases management. It has even been reported that they possess potent 
antioxidant activity several times higher than that of vitamin C and vitamin E [162]. Among the most 
representative catechins are: (−)-epigallocatechin-3-gallate (EGCG), (−)-epigallocatechin(−)-
epicatechin-3-gallate, (−)-epicatechin and (+)-catechin. EGCG is the most abundant and biologically 
active [163]. Specifically, EGCG has many pharmacological effects that have been reported to 
promote overall health. Actually, the antioxidant and free radical scavenger properties of EGCG are 
believed to be primarily responsible for the protective effect of tea consumption against the risks of 
cancer, neuron degeneration and coronary artery diseases [164–166]. EGCG alone has been reported to 
exert a variety of biological effects, including anti-oxidant, antibacterial, anti-inflammatory and 
anticarcinogenic activities [167–170]. 
As for its anticancer effects, EGCG is known to induce apoptosis in various types of tumor cells, 
but has little or no effect on normal cells [171–173]. More recently, it was reported that EGCG also 
could induce the apoptotic cell death of osteoclast-like multinucleated cells in a dose dependent 
manner [174]. EGCG has been shown to modulate caspase activation [175,176], but the precise 
mechanism by which EGCG induces apoptosis and modulates caspase activation remains to be 
elucidated. In addition, several in vitro assays have also reported that EGCG inhibits osteoclast 
formation [93,177,178]. Regarding possible mechanisms under this effect, Oka et al. [177] using 
osteoclast precursor cell found that EGCG had an inhibitory effect on formation and differentiation to 
osteoclasts which occurred via matrix metalloproteinase (MMP) suppression. Likewise,  
Kamon et al. [178] reported that EGCG reduced osteoclast formation by inhibiting osteoblast 
differentiation, since osteoblasts are known to be involved in the differentiation of osteoclasts through 
the production of RANKL. Such effects of catechins would be useful for prophylaxis or treatment of 
inflammatory bone disease, such as periodontitis [179]. Actually, catechins, mainly EGCG, have 
contributed to the prevention [180] and healing [181] of periodontal tissue destruction in different 
animal models in spite of different administration methods having been tested, including oral 
administration [180,182], gingival [182] or intraperitoneal injections [181] and topical application as a 
component of a dentrifice [180]. In most of cases, a decrease of osteoclast number and activity was 
also observed [181–183], which could be due to the effects of catechins on the pathways mentioned. 
Additionally, it has been noted that these positive effects were also related to decreased gingival 
oxidative stress, at least at the lipidic and proteic levels [180]. Further, some evidence in humans also 
supports this interest in catechins. An epidemiological study indicated an inverse association between 
green tea intake and clinical periodontal parameters (probing depth, clinical attachment level and 
bleeding on probing) [184], which could be due, as other effects, to its catechins content. In the same 
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sense, a clinical study also reported that the slow-release local delivery of green tea catechins 
strengthened the effects of traditional periodontal treatment on improvement of periodontitis [185]. 
Along with the effect on osteoclasts, catechins also have shown to inhibit some enzymatic activities 
related to periodontal tissue breakdown. In skin, EGCG has been shown to inhibit the infiltration of 
leukocytes and myeloperoxidase activity along with a decrease UV-B induced erythema [155]. EGCG 
has been shown to inhibit the activity [186–189] and expression [190,191] of collagenase (MMP-2) 
and gelatinase (MMP-9).  
Catechins also show an important role in suppression of inflammatory infiltrate in periodontal tissue 
after periodontal disease induction [181,183]. Such an effect on inflammation has also been observed 
in other tissues [155,192]. This anti-inflammatory effect has been related to reduction of  
pro-inflammatory cytokine levels, namely of IL-1β [182,183], IL-6 [172,193,194] and  
TNFα [180,183,195], which seems controlled at the transcriptional level [183,195,196]. Similarly, 
inhibition of the production of these pro-inflammatory cytokines in response to bacterial factors such 
as LPS has been reported in different in vitro assays [197]. Moreover, it has been reported that 
catechins enhance the production of the anti-inflammatory cytokine IL-10 [195,196]. Down-regulation 
of the expression of pro-inflammatory cyokines such as TNFα, IL-1β and IL-6 would lead to a 
decrease in osteoclast number and activity, which results in reduced bone loss [183]. Moreover, in a 
murine model a decrease of Cyr61-synthesizing osteoblasts has been reported, which subsequently 
would diminish macrophage chemotaxis into the lesions [181]. The effect of EGCG on Cyr61 
production deserves further investigation because Cyr61 might be involved in inflammatory bone loss 
by promoting pathogenic angiogenesis and macrophage recruitment [181]. In fact, EGCG has been 
demonstrated to inhibit angiogenesis by suppressing the activation of vascular endothelial growth 
factor (VEGF) receptor in endothelial cells [142,198]. 
9.3.2. Theaflavins 
Theaflavins are the major polyphenols in black tea. These compound are categorized into the 
following forms: theaflavin, theaflavin-3-gallate, theaflavin-3ʹ-gallate, and theaflavin-3,3ʹ-digallate 
(TFDG). In particular, it has been reported that TFDG has stronger biological effects, including an 
antioxidant effect, compared with other theaflavins [193,199]. As previous compounds, TFDG 
prevented TNF superfamily 14-mediated IL-6 production in human gingival fibroblast cultures by 
similar inhibitory actions on ERK, JNK and NF-kB activation as well as receptor expression of the 
tumor necrosis factor superfamily 14 [200]. Thus, it could also suppress NO production by the iNOS 
expression inhibition. This suggests that theaflavins, namely TFDG, could be used as catechins for 
periodontal disease management, but there is need for more studies with these compounds. 
9.3.3. Proanthocyanidins 
Proanthocyanidins are among the most abundant phenolic compounds in grape seeds (Vitis 
vinifera). These molecules have been associated, at least in part, with the protective effect of red wine 
for atherogenesis and cardiovascular diseases [201,202]. In support of this, recent studies have shown 
that oligomeric proanthocyanidins in grape seeds prevent heart disease and skin aging [203], and that 
they possess anti-inflammatory, antiarthritic and antitumor-promoting activities [204]. As other 
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compounds reviewed, possible mechanisms by which these phenolic compounds might exert their 
protective effects include antioxidant properties, oxygen and nitrogen scavenging abilities [201,202], 
and inhibitory effects on both arachidonic acid cascade [201] and prostaglandins modulation [204,205]. 
Interestingly, grape seed proanthocyanidins have been shown to exert a much stronger oxygen-free 
radical scavenging effect than vitamins C and E [206]. Several in vitro assays have offered similar 
result in relation to periodontal disease. In murine RAW 264.7 cells, treatment with non-toxic 
concentrations of grape seed proanthocyanidin extract, strongly decreased NO and ROS production 
along with iNOS protein expression after simulation with LPS of two major periodontopathogens,  
A. actinomycetemcomitans or F. nucleatum [60]. Likewise, it was found that a proanthocyanidin-rich 
cranberry fraction possessed the capacity to reduce the production of inflammatory mediators by  
LPS-stimulated macrophages and gingival fibroblasts [207,208] and to inhibit host extracellular matrix 
destructive enzyme production and activity [209]. In addition, the same cranberry fraction could 
prevent biofilm formation by Porphyromonas gingivalis [210] a major etiological agent of chronic 
periodontitis. Given these results, proanthocyanidins should be considered a potential agent in the 
prevention of periodontal disease. 
10. Conclusions 
The present review was performed to explore whether naturally occurring non-nutrient phenolic 
compounds present in various foods and plants could be useful for periodontal disease because of their 
antioxidant effect or activity. In this context, in vitro studies have shown that many phenolic 
compounds in foods and their derivatives could help to reduce oxidative stress triggered by the 
presence of periodontal bacterial products (in particular by LPS). This seems largely due to 
immunomodulatory actions [130,131,208,210], to the promotion of the antioxidant enzymes activity, 
such as HO-1 [95,125,130,145], and/or to the inhibition of enzymes that contribute to  
RNS and ROS production such as iNOS [61,125,142,194,210]. Although the number of  
compounds used in animal models has been low, these studies have allowed to observe that  
many of the compounds improve or prevent the development of this pathology  
both in terms of periodontal inflammation [26,51,67,83,117,181] and periodontal tissue  
breakdown [26,29,51,83,93,110,136,183,184]. In turn, these effects have been shown to be  
associated with lower levels of nitro-oxidative stress [93,130,181] and proinflammatory  
mediators [83,93,110,181–184]; and consequently with lower levels of oxidative damage [18,93]. 
However, very few studies evaluating their actions in humans are reduced only to CoQ [39,47,52] and 
catechins [186] that in most of cases were combined with previous mechanical treatments [39,52,186]. 
Apart from these, the sample sizes used were small. Hence, many more interventions in humans are 
needed to evaluate the possible effects of different compounds on periodontal diseases, particularly 
those that are more ubiquitous, although for ethical reasons, these compounds should be combined 
with other treatments. In this sense, epidemiological studies evaluating the content in the diet  
of these compounds could also be very interesting to identify possible targets before performing  
experimental trials. 
  
Antioxidants 2015, 4 462 
  
 
Table 1. Main studies in relation to naturally occurring antioxidant phenolic compounds of interest in periodontal disease. 
Compound 
Study 
Type 
Sample Studied  
(age/weight), n 
Adminitration (Dosage,  
Frecuency and Duration) 
Main Effect/s Reference 
Thymoquinone Animal 
Male Wistar rats with ligature-induced 
periodontitis (300 ± 10 g), n = 8 
Intragastric (10 mg/kg, daily for 11 days) 
ABL, inflammatory infiltrate and osteoclasts n° 
were reduced; osteoblasts activity was maintained 
[25] 
Coenzyme Q NCT 
Patients under routine care for 
periodontitis (N/A) n = 8 
Oral (N/A) 
Periodontal inflammation and periodontal  
pocket depth decreased 
[46] 
 RCT 
Chronic periodontitis patients  
(20–55 year), n = 3–6 
Topical (CoQ10 in a vegetable oil base in 
ratio of 1:9 in gel-form for 2/4 weeks) 
Plaque index, gingival index, gingival bleeding 
index, periodontal probing pocket depth, and 
clinical attachment level were improved 
[38,51] 
 Animal 
Male Fischer rats without additional 
treatments (8/16 weeks) n = 24 
Topical (ointment with 1% rCoQ10  
daily for 2/4 months) 
Osteoclast differentiation associated to aging 
decreased. The same conditions lowered gene 
periodontal expression of caspase-1 and IL-1β 
[50] 
Gallic acid In vitro 
RAW 264.7 cells stimulated with LPS of  
A. actinomycetemcomitans or F. nucleatum 
Preincubation (4 mg/ml for 2 h) NO production was strongly inhibited [60] 
Hidroxytyrosol Animal 
New Zealand White rabbits with  
dietary-induced atherosclerosis (2.5 kg),  
n = 8 
Dietary supplementation  
(25 mg/kg daily for 30 days) 
Endothelial activation was decreased [66] 
Mangiferin Animal 
Male Wistar rats with ligature-induced 
periodontitis (180 g), n = 4–7 
Oral (100 mg/kg daily for 7 days) 
ABL and cellularity were reduced. COX-2 
expression and the inhibition of rolling and 
adhesion of leukocyte 
[82] 
Resveratrol Animal 
Male Wistar rats with ligature-induced 
periodontitis (8 weeks), n = 6 
Oral supplementation  
(10 mg/kg daily melinjo resveratrol in 
drinking water for 20 days) 
ABL was prevented and systemic levels of 8OH-
dG, dityrosine, nitrotyrosine and proinflammatory 
cytokines (IL-1β IL-6, and TNF-α) were reduced 
[92] 
 Animal 
Male Wistar ratswith ligature-induced 
periodontitis (12 weeks), n = 12 
Intragastric (10 mg/kg daily for 30 days) 
ABL and gingival IL-17 were reduced, but L-1β 
and IL-4 levels were unaffected 
[28] 
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Table 1. Cont. 
Verbascoside Animal 
Male Sprague–Dawley rats with ligature-
induced periodontitis (280–400 g), n = 10 
Oral (2 mg/kg daily for 8 days) 
Gingivomucosal tissue injury and multiple 
inflammation and oxidative stress markers  
(MPO activity, activation of poly(ADP-ribose) 
polymerase TBARS, nitration of tyrosine residues, 
expression of NF-κB , iNOS, Bax and Bcl-2)  
were decreased 
[98] 
Quercetin Animal 
Male Sprague–Dawley rats LPS-injected 
(6 weeks), n = 4 
Oral (75 mg/kg, daily for 8/12 days) 
Osteoclasts induction and inflammatory infiltrate 
were reduced. Bone crest levels were more apical 
and coronal alveolar level was higher than  
in the controls 
[116] 
 Animal 
Male Balb/c mice with A. 
actinomycetemcomitans  
infection (6–7 weeks), n = 5 
Subcutaneous injections  
(100 mg/kg daily for 15 days) 
ABL and gingival levels of IL-1β, TNF-α, IL-17, 
RANKL, and ICAM-1 were reduced 
[109] 
Kaempferol In vitro 
RAW246.7 cell stimulated by LPS from  
P. intermedia 
Coincubation  
(10–100 μM for 24 h) 
NO production was strongly inhibited [124] 
Isorhamnetin In vitro 
RAW264.7 cells stimulated by LPS from 
P. intermedia 
Coincubation  
(12.5–50 μM for 24 h) 
IL-6 mRNA and protein levels  
were down-regulated 
[129] 
Luteolin In vitro 
RAW264.7 cells stimulated by LPS  
from E. coli 
Preincubation  
(10 μM for 30 min/60 min) 
 Activation of several MAPK family members and 
TNF-a release were reduced 
[131] 
 In vitro 
Human gingival fibroblasts stimulated by 
LPS from Salmonella enteritidis 
Preincubation  
(10 μM for 30 min) 
 NO synthesis and cellular proliferation inhibition  
were suppressed 
[132] 
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Table 1. Cont. 
Baicalin Animal 
Male Sprague–Dawley rats with ligature-
induced periodontitis (8 weeks),  
n = 9 groups 
Intragastric (50, 100 or 200 mg/kg,  
daily for 7 days)  
ABL and collagen fibers loss were reduced; which 
was associated with COX-2 and iNOS levels 
down-regulation 
[134] 
 In vitro 
Human periodontal ligament cells and 
gingival fibroblats stimulated by IL-1β 
Coincubation (N/A for 1 h)  
Pro-MMP-1 secretion and MMP-3 expression 
were reduced 
[136] 
 In vitro RAW 264.7 cells stimulated by LPS Coincubation (5–40 μM for 24 h) iNOS expression was reduced [141] 
Apigenin In vitro 
Human periodontal ligament cells 
stimulated by nicotine and LPS from  
P. gingivalis 
Preincubation (40 μM for 4 h) 
NO production and up-regulation of iNOS, COX-2 
and several proinflammatory factors (PGE2,  
IL-1β, TNF-α, IL-6, and IL-12) were inhibited 
[144] 
Nobiletin and 
tangeretin 
In vitro RAW264.7 cells stimulated by LPS 
(30 μM for 5 days) in the presence of 
sRANKL (100 ng/mL) 
Osteoclast formation and bone resorption and 
RANKL-induced osteoclastogenesis was reduced 
[150] 
Catechins RCT 
Volunteers with advanced periodontitis  
but with no systemic disorders  
(41–64 years), n = 6 
Topical (HPC strips containing GTC,  
once a w for 8 weeks) 
Pocket depth and the proportion of BPR  
were decreased in combination with  
mechanical treatment 
[185] 
 Animal 
Male Sprague–Dawley Rats with ligature-
induced periodontitis (150–180 g), n = 24 
Intragastric (200 mg/kg EGCG daily  
for 1/2/4 weeks) 
ABL and collagen destruction were decreased 
which was associated to a reduction of IL-6 and  
TNF-α expression 
[183] 
 Animal 
Male Wistar rats with periodontal 
inflammation induced by LPS from E. coli 
and proteases from S. griseus (8 weeks),  
n = 11 
Topical (dentifrice with 1.0% GTC daily 
for 4 weeks) 
Inflammatory infiltrate was reduced which was 
accompanied by lower gingival hexanoyl-lysine, 
nitrotyrosine, and TNF-α 
[180] 
  
Antioxidants 2015, 4 465 
 
 
Table 1. Cont. 
 Animal 
Male BALB/c mice receiving gingival 
injections of LPS from E. coli (7 weeks),  
n = 6 
Oral supplementation (in drinking water 
with 1% Sunphenon BG 1 free acess  
for 20 days) 
ABL and IL-1β expression  
were decreased 
[182] 
 Animal 
Male BALB/c mice receiving gingival 
injections of LPS from E. coli (7 weeks),  
n = 6 
Gingival injection (1% Sunphenon BG 1 
every 48 h for 20 days) 
ABL and IL-1β expression  
were decreased 
[182] 
 In vitro 
Osteoclasts from mouse bone marrow 
macrophagesstimulated  
by RANKL 
Coincubation (2–10 μg/mL Sunphenon  
BG 1 for 4 days) 
Osteoclasts n° decreased in  
a dose-dependent manner  
[182] 
 In vitro 
RAW264.7 cells stimulated by LPS  
from E. coli 
Preincubation  
(50 mmol/L of EGCG for 2 h) 
TNFα production and mRNA expression were 
decreased as well as nuclear  
NF-κB–binding activity  
[195] 
 In vitro 
Human gingival fibroblasts stimulated by 
oncostatin M 
Preincubation (5/50 μg/mL EGCG or ECG, 
for 1 h) 
CXCL10 production was prevented [193] 
 In vitro 
Human gingival fibroblast stimulated by 
tumor necrosis factor superfamily 14 
Preincubation (5/50 mg/mL EGCG or ECG 
for 1 h) 
IL-6 production was prevented [199] 
Theaflavins  In vitro 
Human gingival fibroblast stimulated by 
tumor necrosis factor superfamily 14 
Preincubation (5/50 mg/mL TFDG for 1 h) IL-6 production was prevented [199] 
  
Antioxidants 2015, 4 466 
 
 
Table 1. Cont. 
Proanthocyanidins In vitro 
Human macrophages stimulated by LPS 
from different periodontopathogens 2 
Preincubation (10–50 μg/mL of a 
Proanthocyanidin-rich cranberry  
fraction for 2 h) 
IL-1β, IL-6, IL-8, TNF-α, and RANTES 
production was reduced 
[206] 
 In vitro 
Human gingival fibroblasts stimulated by 
LPS from A. actinomycetemcomitans 
Preincubation (10-50 μg/mL of a 
Proanthocyanidin-rich cranberry  
fraction for 2 h) 
IL-6, IL-8, and PGE2 production  
and increase of COX-2 expression were inhibited 
[207] 
 In vitro 
Human macrophages and gingival 
fibroblasts stimulated by LPS from  
A. actinomycetemcomitans  
Preicubation (10–150 μg/mL of a 
proanthocyanidin-rich cranberry  
fraction for 2 h) 
MMP-3 and MMP-9 production and activity were 
inhibited 
[208] 
 In vitro 
RAW 264.7 cells, simulated by LPS from  
A. actinomycetemcomitans or F. nucleatum 
Grape seed proanthocyanidin extract  
(4 mg/mL for 2 h) 
NO and ROS production and iNOS l  
levels decreased 
[60] 
1 Sunphenon BG contains 91.3% polyphenol and 76.6% catechins, consisting of 45.9% EGCG, 9.6% epigallocatechin, 8.6% ECG, 5.3% epicatechin and others; 2 A. actinomycetem comitans, F. nucleatum subsp. 
Nucleatum, P. gingivalis, Treponema denticola, Tannerella forsythia, and E. coli. Abbreviations and acronyms: 8OH-dG: 8-hydroxydeoxiguanoxine; A. actinomycetemcomitans: Aggregatibaceter actinomycetemcomitans; 
ABL: Alveolar bone loss; BPR: Gram-negative anaerobic rods; COX-2: Cyclooxygenase-2; CXCL10: C-X-C motif chemokine 10; E. coli: Escherichia coli; ECG: Epicatechin gallate; EGCG: Epigallocatechin 
gallate; F. nucleatum: Fusobacterium nucleatum; GTC: Green tea catechins; h: hours; HPC: Hydroxypropyl cellulose; ICAM-1: Intercellular adhesion molecule; IL: Interleukin; iNOS: Inducible nitric oxide 
synthase; LPS: Lypopolysaccharide; MMP: Matrix metalloproteinase; MPO; Myeloperoxidase; n: sample size per group; N/A; not available; NF-κB; Nuclear factor κB; NTC: non-controlled trial;  
P. gingivalis: Porphyromonas gingivalis; P. intermedia: Prevotella intermedia; PGE2: Protaglandin E2; RANKL: Receptor activator for nuclear factor κ B ligand; RANTES: Regulated on activation normal  
T-cell expressed and secreted; ROS: Reactive oxygen species; RCT: Randomized controlled trial; S. griseus: Streptomyces griseus; TBARS: Tiobarbituric acid reactive sustances; TFDG: Theaflavin digallate;  
TNF-α: Tumor necrosis factor-α. 
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